Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences:
A live webcast of each presentation will be available through the Investor Relations section of Geron's website under Events. Following the presentations, the webcasts will be archived and available for replay for a period of 30 days.
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com.
These press releases may also interest you